Cargando…
The path to the clinic: a comprehensive review on direct KRAS(G12C) inhibitors
The RAS oncogene is both the most frequently mutated oncogene in human cancer and the first confirmed human oncogene to be discovered in 1982. After decades of research, in 2013, the Shokat lab achieved a seminal breakthrough by showing that the activated KRAS isozyme caused by the G12C mutation in...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767686/ https://www.ncbi.nlm.nih.gov/pubmed/35045886 http://dx.doi.org/10.1186/s13046-021-02225-w |